The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform
Yoshito Komatsu - One of the best experts on this subject based on the ideXlab platform.
-
retrospective cohort study on the risk factors of admission due to serious adverse events during s 1 tegaful gimeracil Oteracil Potassium containing chemotherapy for gastric cancer
Journal of Clinical Oncology, 2012Co-Authors: Yasuyuki Kawamoto, Satoshi Yuki, Yoshimitsu Kobayashi, Koji Oba, Hideyuki Hayashi, Hiroshi Nakatsumi, Yoshito KomatsuAbstract:141 Background: S-1 (tegaful, gimeracil, Oteracil Potassium) containing regimens are widely used as first line chemotherapy for metastatic or unresectable gastric cancer in Japan. Because patients ...
Yasufumi Sawada - One of the best experts on this subject based on the ideXlab platform.
-
the first case of phenytoin intoxication associated with the concomitant use of phenytoin and ts 1 a combination preparation of tegafur gimeracil and Oteracil Potassium
Cancer Chemotherapy and Pharmacology, 2008Co-Authors: Aiko Tsuda, Hisakazu Ohtani, Satoko Hori, Junshin Fujiyama, Akiko Miki, Yasufumi SawadaAbstract:Purpose We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur (FT).
-
Development of a Pharmacokinetic Model to Optimize the Dosage Regimen of TS-1, a Combination Preparation of Tegafur, Gimeracil and Oteracil Potassium
Drug metabolism and pharmacokinetics, 2007Co-Authors: Saori Inoue, Hisakazu Ohtani, Masayuki Tsujimoto, Satoko Hori, Yasufumi SawadaAbstract:Summary: Background TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. UFT is a combination preparation of tegafur with uracil, which also inhibits DPD, though less potently; UFT has a higher content of tegafur than that in TS-1. We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT. Methods We developed a model incorporating the inhibition of DPD by gimeracil and uracil, and fitted the model to the observed kinetics of tegafur and 5-FU after the administration of TS-1 and UFT. Then, we simulated the plasma 5-FU profiles in patients with renal dysfunction and those after replacement of TS-1 with UFT and compared them with the observed profiles. Results The developed model could appropriately describe the plasma concentration profiles of 5-FU and tegafur after the administration of TS-1 in patients with normal and impaired renal function. Conclusion The developed model may be useful to optimize the dosage regimen of TS-1 under various clinical conditions.
Yasuyuki Kawamoto - One of the best experts on this subject based on the ideXlab platform.
-
retrospective cohort study on the risk factors of admission due to serious adverse events during s 1 tegaful gimeracil Oteracil Potassium containing chemotherapy for gastric cancer
Journal of Clinical Oncology, 2012Co-Authors: Yasuyuki Kawamoto, Satoshi Yuki, Yoshimitsu Kobayashi, Koji Oba, Hideyuki Hayashi, Hiroshi Nakatsumi, Yoshito KomatsuAbstract:141 Background: S-1 (tegaful, gimeracil, Oteracil Potassium) containing regimens are widely used as first line chemotherapy for metastatic or unresectable gastric cancer in Japan. Because patients ...
Motonori Sairenji - One of the best experts on this subject based on the ideXlab platform.
-
feasibility study of adjuvant chemotherapy with s 1 ts 1 tegafur gimeracil Oteracil Potassium for gastric cancer
Gastric Cancer, 2004Co-Authors: Taira Kinoshita, Atsushi Nashimoto, Yoshitaka Yamamura, Takeshi Okamura, Mitsuru Sasako, Junichi Sakamoto, Hiroshi Kojima, Masahiro Hiratsuka, Kuniyoshi Arai, Motonori SairenjiAbstract:Background We conducted a feasibility study using S-1, a novel oral derivative of 5-fluorouracil, as postoperative adjuvant chemotherapy for curatively resected gastric cancer patients.
Yoshihiko Maehara - One of the best experts on this subject based on the ideXlab platform.
-
feasibility study of postoperative adjuvant chemotherapy with s 1 tegaful gimeracil Oteracil Potassium for non small cell lung cancer logik 0601 study
Lung Cancer, 2010Co-Authors: Tokujiro Yano, Koji Yamazaki, Riichiroh Maruyama, Shoji Tokunaga, Fumihiro Shoji, Hidefumi Higashi, Sadanori Takeo, Yukito Ichinose, Yoshihiko MaeharaAbstract:Abstract Introduction The feasibility of using S-1, a novel oral dihydropyrimidine dehydrogenase (DPD)-inhibitory 5-fluorouracil, as postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) was analyzed. Methods Adjuvant chemotherapy consisted of eight courses (2-week administration and 1-week withdrawal) of S-1, at 80–120 mg/body per day in an outpatient setting. From July 2006 through March 2007, 30 patients were enrolled in this multi-institutional trial. Results The planned eight courses of S-1 administration were accomplished to 17 patients (56.7%; 95% confidence interval 37.4–74.5%). Two patients discontinued the treatment due to the disease recurrence, and therefore the completion rate was calculated to be 60.7%. The completion rate in patients younger than 70 years old was 78.6% while it was 42.9% in those of 70 years old or older. In seven patients including five elderly patients (≥70 years old), S-1 administration was discontinued due to subjective symptoms, such as anorexia, during the early courses. The rate of patients with mild renal impairment (60 ≤ creatinine clearance Conclusion Postoperative long-term administration of S-1 seems feasible as adjuvant chemotherapy for NSCLC, with few adverse events except for the early development of anorexia, especially in the elderly patients.
